1. Metabolic Enzyme/Protease
    Cell Cycle/DNA Damage
    Autophagy
  2. HSP
    Autophagy

NVP-AUY922 (Synonyms: Luminespib; AUY922; VER-52296)

Cat. No.: HY-10215 Purity: 98.17%
Data Sheet SDS Handling Instructions

NVP-AUY922 is a highly potent HSP90 inhibitor with IC50 of 13 nM/21 nM for for HSP90α/β, respectively, and has weaker potency against the HSP90 family members GRP94 and TRAP-1.

For research use only. We do not sell to patients.
NVP-AUY922 Chemical Structure

NVP-AUY922 Chemical Structure

CAS No. : 747412-49-3

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
5 mg $50 In-stock
10 mg $70 In-stock
25 mg $140 In-stock
100 mg $350 In-stock
200 mg $600 In-stock
500 mg $1100 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Customer Review

    NVP-AUY922 purchased from MCE. Usage Cited in: Stem Cell Res. 2014 Sep;13(2):284-99.

    HSP90 inhibition affects ciliation. 24 h treatment with 100 nM AUY922 significantly affects ciliation, under 20% (left) O2 tension but not 5% O2 tension (right).
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    NVP-AUY922 is a highly potent HSP90 inhibitor with IC50 of 13 nM/21 nM for for HSP90α/β, respectively, and has weaker potency against the HSP90 family members GRP94 and TRAP-1.

    IC50 & Target

    IC50: 13 nM (HSP90α), 21 nM (HSP90β)

    In Vitro

    AUY922 significantly attenuates changes in immunophenotype and signal transducer and activator of transcription 3 (STAT3) signaling induced by CD40L-fibroblast co-culture but has no effect on the viability of CLL cells. AUY922 in combination with fludarabine is significantly more effective at inducing apoptosis in cells in co-culture than either drug alone, an effect that is irrespective of ATM/TP53 dysfunction[1]. NVP-AUY922 binds to the NH2-terminal nucleotide site in HSP90. NVP-AUY922 inhibits HSP90 family members GRP94 and TRAP-1 with IC50 values of 535 nM and 85 nM, respectively. NVP-AUY922 induces marked accumulation in either GEC1 or G1 plus G2-M phases in most cell lines[2]. NVP-AUY922 shows great inhibition of pancreatic cancer cells with IC50 of at 10 nM. VP-AUY922 (10 nM for 20 h) reduces the expression and the epidermal growth factor (EGF)-mediated (40 ng/mL) activation of EGFR and substantially disrupts EGF signaling in terms of diminishing downstream phosphorylation of ERKThr202/Tyr204. NVP-AUY922 (10 nM) significantly blocks pancreatic cancer cell migration and invasion both in the absence and presence of EGF[3].

    In Vivo

    NVP-AUY922 (50, 75 mg/kg, i.p.) significantly inhibits tumor growth rate, reducing the mean weights of tumors on day 11[2]. NVP-AUY922 (50 mg/kg/week, 3×25 mg/kg/week) significantly reduces tumor growth rates and lowers tumor weights in the L3.6pl pancreatic cancer cell-bearing mice model[3].

    Clinical Trial
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 2.1480 mL 10.7402 mL 21.4804 mL
    5 mM 0.4296 mL 2.1480 mL 4.2961 mL
    10 mM 0.2148 mL 1.0740 mL 2.1480 mL
    Please refer to the solubility information to select the appropriate solvent.
    Cell Assay
    [2]

    Cell lines are grown in DMEM/10% FCS, 2 mM glutamine, and nonessential amino acids in a humidified atmosphere of 5% CO2 in air as described. All lines are free of Mycoplasma. Cell proliferation is determined using the sulforhodamine B (SRB) assay for tumor cells and prostate epithelial cells, the WST-1 assay for MCF10A and HB119, or an alkaline phosphatase assay for HUVEC and HDMEC. GI50 is the compound concentration inhibiting cell proliferation by 50% compared with vehicle controls. Cell cycle analysis is as described. Active caspase-3/7 is measured using a homogenous caspase assay kit. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [2]

    NVP-AUY922 is dissolved in DMSO and diluted in sterile saline/Tween 20.

    For efficacy studies, human tumor xenografts are established s.c. in athymic mice. WM266.4 cells are also injected i.v. to generate experimental lung metastases and PC3LN3 prostate carcinoma cells are implanted into the prostates of male mice. Dosing with NVP-AUY922 commences when tumors are well established using schedules described. Tumor growth is monitored and at study end samples are harvested for analysis. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    465.54

    Formula

    C₂₆H₃₁N₃O₅

    CAS No.

    747412-49-3

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 62 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    NVP-AUY922
    Cat. No.:
    HY-10215
    Quantity: